

Category No.

11

Ref. No.

458

## Abstract Reproduction Form B-1

Author(s):

R.U. Anderson,<sup>1</sup> R. Appell,<sup>2</sup> M. Gittelman,<sup>3</sup> J. Kaufman,<sup>4</sup> D. Mobley,<sup>5</sup>  
D. Saltzstein,<sup>6</sup> for the Ditropan® XL Study GroupInstitution  
City  
Country<sup>1</sup>Stanford University Medical Center, Stanford, CA; <sup>2</sup>The Cleveland Clinic  
Foundation, Cleveland, OH; <sup>3</sup>South Florida Medical Research, Aventura, FL;  
<sup>4</sup>Urology Research Options, Aurora, CO; <sup>5</sup>Research for Health, Inc., Houston,  
TX; <sup>6</sup>Urology San Antonio USA San Antonio, TX;Title (type in  
CAPITAL  
LETTERS)**EFFICACY, SAFETY AND TOLERABILITY OF ONCE-DAILY  
EXTENDED-RELEASE OXYBUTYNIN CHLORIDE IN ELDERLY  
PATIENTS**

**Aims of Study.** We performed a meta-analysis to examine the efficacy, safety, and tolerability of a new, once-daily, extended-release form of oxybutynin in elderly patients with urge incontinence (UI), a common symptom of overactive bladder.

**Methods.** Patients (n=159) age 65 and over from three adjustable-dose clinical trials were included in the meta-analysis. Patients typically adjusted their dose of once-daily, extended-release oxybutynin within the range of 5-30 mg/day for a balance of efficacy and tolerability. Safety and efficacy data were collected in daily diaries and during office visits.

**Results.** The number of UI episodes decreased 81% from 20.7 per week at baseline to 3.9 per week at the end of the study. Complete continence was reported by 40.1% of patients at the end of the study. During the study 5.7% of patients reported severe anticholinergic effects, including 3.8% reporting severe dry mouth.

**Conclusions.** In these studies, once-daily extended-release oxybutynin was effective for the treatment of UI. This treatment has a favorable safety profile in elderly patients.

Source of Funding: ALZA Corp. on behalf of Crescendo Pharmaceuticals Corp., Palo Alto, CA